title: Glucagon-like peptide 1--a cardiologic dimension.
abstract: Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.
authors.affiliation: Department of Biomedical Sciences and The Danish National Foundation Research Center for Heart Arrhythmia, University of Copenhagen, Copenhagen, Denmark. m.treiman@mfi.ku.dk
authors.forename: Marek
authors.initials: M
authors.lastname: Treiman
authors.forename: Mikkel
authors.initials: M
authors.lastname: Elvekjaer
authors.forename: Thomas
authors.initials: T
authors.lastname: Engstrøm
authors.forename: Jan Skov
authors.initials: JS
authors.lastname: Jensen
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use*; D006331:Heart Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D002317:Cardiovascular Agents; D052216:Glucagon-Like Peptide 1